STOCK TITAN

Waterdrop (NYSE: WDH) grows Q1 2026 revenue 64.8% and returns cash

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Waterdrop Inc. reported strong top-line growth but softer earnings for the first quarter of 2026. Net operating revenue reached RMB1,242.2 million (US$180.1 million), up 64.8% year-over-year but down 12.0% from the prior quarter.

Operating profit was RMB80.0 million (US$11.6 million), slightly above RMB75.9 million a year earlier, while net profit attributable to ordinary shareholders was RMB98.4 million (US$14.3 million), below both the first and fourth quarters of 2025. Adjusted non-GAAP net profit was RMB106.3 million (US$15.4 million).

Insurance-related income rose 74.1% year-over-year, with premiums for pre-existing condition insurance up 24.3%. Revenue from digital clinical trial solutions was about RMB24.2 million, a 5.4% year-over-year increase. As of March 31, 2026, cash position was RMB2,880.7 million (US$417.6 million). As of May 31, 2026, the company had repurchased approximately 61.8 million ADSs for about US$120.1 million and paid a cash dividend of about US$10.8 million.

Positive

  • Net operating revenue surged 64.8% year-over-year to RMB1,242.2 million in Q1 2026, led by strong insurance-related income growth of 74.1% and solid expansion in pre-existing condition products.
  • Meaningful capital return to shareholders, with cumulative repurchases of approximately 61.8 million ADSs for about US$120.1 million and a cash dividend of roughly US$10.8 million as of May 31, 2026.

Negative

  • Net profit attributable to ordinary shareholders declined to RMB98.4 million in Q1 2026, below both the same quarter and the fourth quarter of 2025 despite strong revenue growth.
  • Operating costs and expenses rose 71.5% year-over-year to RMB1,162.3 million, outpacing revenue growth and pressuring margins even as the company invests in AI and user acquisition.

Insights

Rapid revenue growth and capital returns offset softer profitability.

Waterdrop delivered net operating revenue of RMB1,242.2 million, up 64.8% year-over-year, driven mainly by its insurance segment and expanding AI-enabled distribution. Insurance-related income grew 74.1%, while pre-existing condition insurance premiums increased 24.3%, underscoring traction in core products.

Profitability was more modest. Operating profit was RMB80.0 million, and net profit attributable to ordinary shareholders declined versus both Q1 and Q4 2025. Non-GAAP adjusted net profit was RMB106.3 million, reflecting share-based compensation and currency effects.

The balance sheet remained strong, with a cash position of RMB2,880.7 million as of March 31, 2026. Management highlighted shareholder returns, having repurchased about 61.8 million ADSs for roughly US$120.1 million and paying a US$10.8 million cash dividend by May 31, 2026. Subsequent filings may provide further detail on how sustained revenue growth translates into earnings.

Net operating revenue RMB1,242.2 million (US$180.1 million) Q1 2026, up 64.8% year-over-year, down 12.0% quarter-over-quarter
Operating profit RMB80.0 million (US$11.6 million) Q1 2026 vs RMB75.9 million in Q1 2025
Net profit attributable to ordinary shareholders RMB98.4 million (US$14.3 million) Q1 2026, below Q1 2025 and Q4 2025 levels
Adjusted non-GAAP net profit RMB106.3 million (US$15.4 million) Q1 2026, excludes share-based compensation and FX effects
Cash position RMB2,880.7 million (US$417.6 million) As of March 31, 2026
Insurance-related income growth 74.1% year-over-year Q1 2026 insurance business performance
ADS repurchases 61.8 million ADSs for about US$120.1 million Cumulative through May 31, 2026
Digital clinical trial revenue RMB24.2 million Q1 2026, up 5.4% year-over-year
non-GAAP financial
"Adjusted net profit attributable to the Company's ordinary shareholders (non-GAAP1) for the first quarter of 2026 was RMB106.3 million"
Non-GAAP refers to financial measures that companies use to show their earnings or performance without including certain expenses or income that are often added back to give a different picture. It matters because it can make a company's results look better or more favorable, but it may also hide important costs, so investors need to look at both GAAP (official rules) and non-GAAP numbers to get a full understanding.
Waterdrop Medical Crowdfunding financial
"we upgraded our AI-assisted risk screening framework for Waterdrop Medical Crowdfunding, improving the speed and consistency of campaign intake"
digital clinical trial solutions financial
"Revenue from digital clinical trial solutions was approximately RMB24.2 million, up 5.4% year-over-year"
ADSs financial
"we had cumulatively repurchased approximately 61.8 million ADSs from the open market with cash for a total consideration of approximately US$120.1 million"
share repurchase programs financial
"Pursuant to the share repurchase programs launched in September 2021, September 2022, September 2023, September 2024, and September 2025"
A share repurchase program is when a company uses its cash to buy back its own stock from the market, reducing the number of shares held by outside investors. For investors this matters because fewer shares can increase each remaining share’s portion of profits and often supports the stock price, like slicing the same pie into fewer pieces so each piece is larger, and it also signals how management prioritizes returning cash versus other uses.
adjusted net profit financial
"Adjusted net profit attributable to the Company's ordinary shareholders represents net profit attributable to our ordinary shareholders excluding share-based compensation"
Adjusted net profit is a company’s reported profit after removing unusual or one-time items—like large legal settlements, asset sales, or restructuring costs—so the number reflects the business’s regular, ongoing earnings. Investors use it like a cleaned-up snapshot of performance to compare results across periods or companies, because it aims to show the income a company can reasonably be expected to produce under normal conditions rather than temporary spikes or drops.
Net operating revenue RMB1,242.2 million +64.8% year-over-year
Net profit attributable to ordinary shareholders RMB98.4 million below Q1 2025 (RMB108.2 million)
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

Form 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE
13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of June 2026

 

Commission File Number 001-40376

 

 

 

Waterdrop Inc.

(Translation of registrant’s name into English)

 

 

 

No. 203 Wangjing Lize Zhongyuan Zone 2

Chaoyang District, Beijing

People’s Republic of China

(Address of principal executive office)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  Form 20-F  x Form 40-F  ¨

 

 

 

 

 

 

EXHIBIT INDEX

 

Exhibit No.   Description
99.1   Press Release—Waterdrop Inc. Announces First Quarter 2026 Unaudited Financial Results

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Waterdrop Inc.
   
  By: /s/ Xiaoying Xu
  Name: Xiaoying Xu
  Title: Head of Finance
   
Date: June 16, 2026  

 

 

 

 

Exhibit 99.1

 

Waterdrop Inc. Announces First Quarter 2026 Unaudited Financial Results

 

BEIJING, June 16, 2026 - Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare services with a positive social impact, today announced its unaudited financial results for the three months ended March 31, 2026.

 

Financial and Operational Highlights for the First Quarter of 2026

 

· Strong Core Business Growth: Net operating revenue for the first quarter rose to RMB1,242.2 million (US$180.1 million), representing a 64.8% year-over-year increase. Insurance-related income for the quarter reached RMB1,145.8 million (US$166.1 million), up 74.1% from the same period in 2025.
  
·Year-Over-Year Operating Profit Improvement: In the first quarter of 2026, operating profit was RMB80.0 million (US$11.6 million), representing a 5.3% year-over-year increase.
  
·Expanded Scale of Medical Crowdfunding: As of March 31, 2026, around 494 million people have cumulatively donated an aggregate of RMB73.5 billion to 3.75 million patients through Waterdrop Medical Crowdfunding.
  
·Continued Expansion in Patient Enrollment: As of March 31, 2026, the Company had cumulatively enrolled 15,512 patients into 1,718 clinical trial programs through the E-Find Platform.

 

Mr. Peng Shen, Founder, Chairman, and Chief Executive Officer of Waterdrop, commented, "2026 marks Waterdrop's tenth anniversary. We opened the year with a solid first-quarter result, underpinned by rapid top-line growth.

 

For our insurance business, we deepened R&D investment to strengthen our traffic infrastructure and user acquisition capabilities. Insurance-related income rose 74.1% year-over-year. On the product side, we aim to bring insurance within reach for more people through inclusive underwriting and affordable pricing. Premiums for pre-existing condition insurance increased 24.3% year-over-year. We also launched 'Shouhu Ruchu,' a competitively priced cancer plan with metastasis coverage and optional recurrence benefits.

 

Our AI deployment continued to enhance operational efficiency. First-year premiums facilitated by our user-facing 'AI Insurance Expert' increased by 17.7% quarter-over-quarter. Our KEYI.AI underwriting assistant has processed more than 10,000 inquiries to date. To further empower our consultants, we launched 'Claw Copilot,' an application built into our CRM system that integrates KEYI.AI, product knowledge base, and a suite of additional AI tools to provide real-time support during customer interactions.

 

During this quarter, we upgraded our AI-assisted risk screening framework for Waterdrop Medical Crowdfunding, improving the speed and consistency of campaign intake and initial screening. We also streamlined localized risk operations by integrating multilingual risk specialists and culturally attuned review workflows, while maintaining strict compliance.

 

In our digital clinical trial business, the E-Find platform leverages proprietary patented technology to match and recommend patients for innovative drug clinical trials based on structured medical records. In the first quarter, we partnered with 243 pharmaceutical companies and contract research organizations and enrolled 957 patients. Revenue from digital clinical trial solutions was approximately RMB24.2 million, up 5.4% year-over-year.

 

As part of our ongoing shareholder return program, as of May 31, 2026, we had repurchased approximately 61.8 million ADSs for about US$120.1 million, and recently paid a cash dividend of approximately US$10.8 million.

 

As we look to the future, we remain dedicated to the enduring purpose that has shaped our journey since day one. In 2026, we aim to move faster toward becoming an AI-native company to strengthen execution and support durable value for our users and shareholders."

 

 

 

 

Financial Results for the First Quarter of 2026

 

Operating revenue, net

 

Net operating revenue for the first quarter of 2026 reached RMB1,242.2 million (US$180.1 million), which represents an increase of 64.8% year-over-year from RMB753.7 million for the same period of 2025. On a quarter-over-quarter basis, net operating revenue decreased by 12.0%.

 

·Insurance-related income includes insurance brokerage income and technical service income. Insurance brokerage income represents brokerage commissions earned from insurance companies. Technical service income is derived from providing analytics and intelligent recommendation service, risk assessment technical service, customer relationship management (“CRM”) system-based technical services and marketing services to insurance companies, insurance brokers, and agency companies. Reinforced by cumulative big data, we provide risk assessment technical services through algorithm-driven verification system assessing risk by analyzing user profiles and medical history, tagging risk levels for hierarchical management that help insurers refine their risk analysis capabilities since 2025. We leverage multi-dimensional consumer insights to deliver analytics and intelligent recommendation services, enabling policyholders to be matched with more suitable products and improving sales efficiency. Our insurance-related income amounted to RMB1,145.8 million (US$166.1 million) in the first quarter of 2026, representing an increase of 74.1% year-over-year from RMB658.0 million for the first quarter of 2025, which was mainly due to the increase in technical service income. Our technical service income amounted to RMB421.0 million (US$61.0 million) in the first quarter of 2026, compared with RMB9.4 million for the same quarter of 2025. On a quarter-over-quarter basis, insurance-related income decreased by 12.6%, due to the decrease in technical service income.

 

·Crowdfunding service fees represent the service income earned when patients successfully withdraw the proceeds from their crowdfunding campaigns. Our role is to operate the Waterdrop Medical Crowdfunding platform to provide crowdfunding related services through the internet, enabling patients with significant medical bills to seek help from caring hearts through technology (the "medical crowdfunding services"). Our medical crowdfunding services generally consist of providing technical and internet support, managing, reviewing and supervising the crowdfunding campaigns, providing comprehensive risk management and anti-fraud measures, and facilitating the collection and transfer of the funds. For the first quarter of 2026, we generated RMB60.7 million (US$8.8 million) in service fees, representing a decrease of 9.5% from RMB67.1 million for the first quarter of 2025. On a quarter-over-quarter basis, crowdfunding service fees slightly decreased by 1.1%.

 

·Digital clinical trial solution income represents the service income earned from our customers mainly including biopharmaceutical companies and leading biotechnology companies. We match qualified and suitable patients for enrollment in clinical trials for our customers and generate digital clinical trial solution revenue for successful matches and we typically charge our customers a fixed unit price per successful match. For the first quarter of 2026, our digital clinical trial solution income amounted to RMB24.2 million (US$3.5 million), representing an increase of 5.4% from RMB23.0 million in the same period of 2025. On a quarter-over-quarter basis, digital clinical trial solution income decreased by 32.2%.

 

Operating costs and expenses

 

Operating costs and expenses increased by 71.5% year-over-year to RMB1,162.3 million (US$168.5 million) for the first quarter of 2026. On a quarter-over-quarter basis, operating costs and expenses decreased by 12.4%.

 

 

 

 

·Operating costs increased by 30.1% year-over-year to RMB486.8 million (US$70.6 million) for the first quarter of 2026, as compared with RMB374.2 million for the first quarter of 2025, which was primarily driven by (i) an increase of RMB53.9 million in costs of referral and service fees, (ii) an increase of RMB38.9 million in the costs for short message service (SMS) costs for new user onboarding and authentication processes; and (iii) an increase of RMB7.3 million in personnel costs. On a quarter-over-quarter basis, operating costs decreased by 28.1% from RMB677.3 million, primarily due to (i) a decrease of RMB201.9 million in costs of referral and service fees, partially offset by (ii) an increase of RMB12.3 million in the costs for SMS.

 

·Sales and marketing expenses increased by 213.8% year-over-year to RMB541.1 million (US$78.4 million) for the first quarter of 2026, as compared with RMB172.4 million for the same quarter of 2025. The increase was primarily due to an increase of RMB361.4 million in marketing expenses for third-party traffic channels. On a quarter-over-quarter basis, sales and marketing expenses increased by 6.8% from RMB506.8 million, primarily due to an increase of RMB29.4 million in marketing expenses for third-party traffic channels.

 

·General and administrative expenses decreased by 4.3% year-over-year to RMB71.7 million (US$10.4 million) for the first quarter of 2026, as compared with RMB74.9 million for the same quarter of 2025. On a quarter-over-quarter basis, general and administrative expenses decreased by 7.0% from RMB77.1 million, due to a decrease of RMB6.5 million in professional service fees.

 

·Research and development expenses increased by 11.5% year-over-year to RMB62.7 million (US$9.1 million) for the first quarter of 2026, as compared with RMB56.2 million for the same period of 2025, which was primarily driven by an increase of RMB6.7 million in cloud server fees and other IT support expenses. On a quarter-over-quarter basis, research and development expenses decreased by 5.2% from RMB66.2 million. The decrease was primarily due to (i) a decrease of RMB4.3 million in personnel costs and share-based compensation expenses, partially offset by (ii) an increase of RMB1.2 million in cloud server fees and other IT support expenses.

 

Operating profit for the first quarter of 2026 was RMB80.0 million (US$11.6 million), as compared with RMB75.9 million for the first quarter of 2025 and RMB83.9 million for the fourth quarter of 2025.

 

Interest income for the first quarter of 2026 was RMB29.1 million (US$4.2 million), as compared with RMB33.8 million for the first quarter of 2025 and RMB34.8 million for the fourth quarter of 2025.

 

Income tax expense for the first quarter of 2026 was RMB6.8 million (US$1.0 million), as compared with income tax expense of RMB13.3 million for the first quarter of 2025 and income tax benefit of RMB41.7 million for the fourth quarter of 2025.

 

Net profit attributable to the Company's ordinary shareholders for the first quarter of 2026 was RMB98.4 million (US$14.3 million), as compared with RMB108.2 million for the same period of 2025, and RMB162.1 million for the fourth quarter of 2025.

 

Adjusted net profit attributable to the Company's ordinary shareholders (non-GAAP1) for the first quarter of 2026 was RMB106.3 million (US$15.4 million), as compared with RMB130.0 million for the same period of 2025 and RMB170.2 million for the fourth quarter of 2025.

 

Cash position2

 

As of March 31, 2026, cash position of the Company was RMB2,880.7 million (US$417.6 million), as compared with RMB3,249.0 million as of December 31, 2025.

 

1See the sections entitled "Non-GAAP Financial Measure" and "Reconciliations of GAAP and Non-GAAP Results" for more information about the non-GAAP measures referred to in this announcement.
2Cash position includes cash and cash equivalents, short-term investments, and long-term debt investments included in long-term investments.

 

 

 

 

Share Repurchase Programs

 

Pursuant to the share repurchase programs launched in September 2021, September 2022, September 2023, September 2024, and September 2025, respectively, we had cumulatively repurchased approximately 61.8 million ADSs from the open market with cash for a total consideration of approximately US$120.1 million as of May 31, 2026.

 

Supplemental Information

 

We organize and report our business in the following operating segments:

 

•Insurance, which mainly includes insurance brokerage service and technical service;

 

•Crowdfunding, which mainly includes crowdfunding service; and

 

•Others, which do not individually or in the aggregate meet the quantitative and qualitative thresholds to be individually reportable and are aggregated.

 

The table below sets forth the segment operating results, with three-month ended March 31, 2026.

 

   For the Three Months Ended 
   March 31, 2025   December 31, 2025   March 31, 2026 
   RMB   RMB   RMB   USD 
   (All amounts in thousands) 
Operating revenue, net                    
Insurance   657,988    1,310,357    1,145,790    166,105 
Crowdfunding   67,131    61,429    60,729    8,804 
Others   28,575    39,462    35,729    5,179 
Total consolidated operating revenue, net   753,694    1,411,248    1,242,248    180,088 
Operating costs and expenses                    
Insurance   (506,575)   (1,164,229)   (992,834)   (143,931)
Crowdfunding   (97,299)   (96,722)   (96,786)   (14,031)
Others   (54,000)   (58,252)   (64,721)   (9,383)
Operating profit/(loss)                    
Insurance   151,413    146,128    152,956    22,174 
Crowdfunding   (30,168)   (35,293)   (36,057)   (5,227)
Others   (25,425)   (18,790)   (28,992)   (4,204)
Total segment operating profit   95,820    92,045    87,907    12,743 
Unallocated items*   (19,927)   (8,181)   (7,954)   (1,152)
Total consolidated operating profit   75,893    83,864    79,953    11,591 
Total other income   41,690    36,538    27,258    3,952 
Consolidated profit before income tax, and share of results of equity method investee   117,583    120,402    107,211    15,543 

 

*The share-based compensation represents unallocated items in the segment information because our management does not consider this as part of the segment operating performance measure.

 

 

 

 

Exchange Rate

 

This announcement contains translations of certain RMB amounts into U.S. dollars ("USD" or "US$") at specified rates solely for the convenience of the reader. Unless otherwise stated, all translations from RMB to USD were made at the rate of RMB6.8980 to US$1.00, the noon buying rate in effect on March 31, 2026 in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the RMB or USD amounts referred could be converted into USD or RMB, as the case may be, at any particular rate or at all. For analytical presentation, all percentages are calculated using the numbers presented in the financial statements contained in this earnings release.

 

Non-GAAP Financial Measure

 

The Company uses non-GAAP financial measure, adjusted net profit attributable to our ordinary shareholders, in evaluating the Company's operating results and for financial and operational decision-making purposes. Adjusted net profit attributable to our ordinary shareholders represents net profit attributable to our ordinary shareholders excluding share-based compensation expense attributable to our ordinary shareholders and foreign currency exchange gain or losses. Such adjustments have no impact on income tax.

 

The non-GAAP financial measure is not presented in accordance with U.S. GAAP and may be different from non-GAAP methods of accounting and reporting used by other companies. The non-GAAP financial measure has limitations as analytical tools and when assessing the Company's operating performance, investors should not consider it in isolation, or as a substitute for net loss or other consolidated statements of comprehensive loss data prepared in accordance with U.S. GAAP. The Company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure. Investors are encouraged to review the Company's historical non-GAAP financial measure to the most directly comparable GAAP measure. Adjusted net profit attributable to our ordinary shareholders presented here may not be comparable to similarly titled measure presented by other companies. Other companies may calculate similarly titled measure differently, limiting its usefulness as a comparative measure to our data.

 

The Company mitigates these limitations by reconciling the non-GAAP financial measure to the most comparable U.S. GAAP performance measure, all of which should be considered when evaluating the Company's performance.

 

For more information on the non-GAAP financial measure, please see the table captioned "Reconciliations of GAAP and Non-GAAP Results" set forth at the end of this press release.

 

Safe Harbor Statement

 

This press release contains statements that may constitute "forward-looking" statements pursuant to the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "aims," "future," "intends," "plans," "believes," "estimates," "likely to" and similar statements. Among other things, quotations in this announcement, contain forward-looking statements. Waterdrop may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Waterdrop's beliefs, plans and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Waterdrop's mission, goals and strategies; Waterdrop's future business development, financial condition and results of operations; the expected growth of the insurance, medical crowdfunding and healthcare industry in China; Waterdrop's expectations regarding demand for and market acceptance of our products and services; Waterdrop's expectations regarding its relationships with consumers, insurance carriers and other partners; competition in the industry and relevant government policies and regulations relating to insurance, medical crowdfunding and healthcare industry. Further information regarding these and other risks is included in Waterdrop's filings with the SEC. All information provided in this press release is as of the date of this press release, and Waterdrop does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

 

 

 

 

Conference Call Information

 

Waterdrop's management team will hold a conference call on June 16, 2026 at 8:00 AM U.S. Eastern Time (8:00 PM Beijing/Hong Kong Time on the same day) to discuss the financial results. Dial-in details for the earnings conference call are as follows:

 

International: 1-412-317-6061
United States Toll Free: 1-888-317-6003
Hong Kong Toll Free: 800-963976
Hong Kong: 852-58081995
Mainland China: 4001-206115
Chinese Line (Mandarin) Entry Number: 4749778
English Interpretation Line (Listen-only Mode) Entry Number: 1011277

 

Participants can choose between the Chinese and the English interpretation lines. Please note that the English interpretation option will be in listen-only mode. Please dial in 15 minutes before the call is scheduled to begin and provide the Elite Entry Number to join the call.

 

Telephone replays will be accessible two hours after the conclusion of the conference call through June 23, 2026 by dialing the following numbers:

 

United States Toll Free: 1-855-669-9658
International: 1-412-317-0088
Chinese Line Access Code: 8479769
English Interpretation Line Access Code: 6416967

 

A live and archived webcast of the conference call will also be available at the Company's investor relations website at http://ir.waterdrop-inc.com/.

 

About Waterdrop Inc.

 

Waterdrop Inc. (NYSE: WDH) is a leading technology platform dedicated to insurance and healthcare service with a positive social impact. Founded in 2016, with the comprehensive coverage of Waterdrop Insurance Marketplace and Waterdrop Medical Crowdfunding, Waterdrop aims to bring insurance and healthcare services to billions through technology. For more information, please visit www.waterdrop-inc.com.

 

For investor inquiries, please contact

 

Waterdrop Inc.

IR@shuidi-inc.com

 

 

 

 

WATERDROP INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(All amounts in thousands, unless otherwise noted)

 

   As of 
   December 31, 2025   March 31, 2026 
   RMB   RMB   USD 
Assets               
Current assets               
Cash and cash equivalents   483,003    751,940    109,008 
Restricted cash   648,450    935,432    135,609 
Short-term investments   530,668    143,805    20,847 
Accounts receivable, net   1,260,464    1,821,836    264,111 
Current contract assets   806,916    879,145    127,449 
Amount due from related parties   209    280    41 
Prepaid expense and other assets   251,084    294,031    42,628 
Total current assets   3,980,794    4,826,469    699,693 
Non-current assets               
Non-current contract assets   295,516    323,671    46,922 
Property, equipment and software, net   255,698    253,567    36,759 
Intangible assets, net   177,140    179,182    25,976 
Long-term investments   2,284,102    2,076,805    301,073 
Right of use assets, net   23,955    21,448    3,109 
Deferred tax assets   2,870    578    84 
Goodwill   80,751    80,751    11,706 
Total non-current assets   3,120,032    2,936,002    425,629 
Total assets   7,100,826    7,762,471    1,125,322 
                
Liabilities and Shareholders' Equity               
Current liabilities               
Amount due to related parties   9,324    9,914    1,437 
Insurance premium payables   684,800    1,009,041    146,280 
Accrued expenses and other current liabilities   1,140,448    1,173,724    170,154 
Short-term loans   47,000    274,675    39,820 
Current lease liabilities   10,888    9,746    1,413 
Total current liabilities   1,892,460    2,477,100    359,104 
Non-current liabilities               
Non-current lease liabilities   12,640    11,034    1,600 
Deferred tax liabilities   43,798    48,522    7,034 
Total non-current liabilities   56,438    59,556    8,634 
Total liabilities   1,948,898    2,536,656    367,738 
                
Shareholders' equity               
Class A ordinary shares   116    116    17 
Class B ordinary shares   27    27    4 
Treasury stock   (16)   (17)   (2)
Additional paid-in capital   6,733,696    6,640,030    962,602 
Accumulated other comprehensive income   43,622    3,373    489 
Accumulated deficit   (1,625,517)   (1,527,145)   (221,390)
Non-controlling interests   -    109,431    15,864 
Total shareholders' equity   5,151,928    5,225,815    757,584 
Total liabilities and shareholders' equity   7,100,826    7,762,471    1,125,322 

 

 

 

 

WATERDROP INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(All amounts in thousands, except for share and per share data, or otherwise noted)

 

 

   For the Three Months Ended 
   March 31, 2025   December 31, 2025   March 31, 2026 
   RMB   RMB   RMB   USD 
Operating revenue, net   753,694    1,411,248    1,242,248    180,088 
Operating costs and expenses(i)                    
Operating costs   (374,218)   (677,337)   (486,812)   (70,573)
Sales and marketing expenses   (172,396)   (506,786)   (541,052)   (78,436)
General and administrative expenses   (74,943)   (77,094)   (71,701)   (10,394)
Research and development expenses   (56,244)   (66,167)   (62,730)   (9,094)
Total operating costs and expenses   (677,801)   (1,327,384)   (1,162,295)   (168,497)
Operating profit   75,893    83,864    79,953    11,591 
Other income                    
Interest income   33,814    34,812    29,088    4,217 
Foreign currency exchange (loss)/gain   (2,103)   111    22    3 
Others, net   9,979    1,615    (1,852)   (268)
Profit before income tax, and share of results of equity method investee   117,583    120,402    107,211    15,543 
Income tax (expense)/ benefit   (13,328)   41,714    (6,785)   (984)
Share of results of equity method investee   -    -    (2,155)   (312)
Net profit   104,255    162,116    98,271    14,247 
Net loss attributable to non-controlling interests shareholders   (3,940)   -    (101)   (15)
Net profit attributable to ordinary shareholders   108,195    162,116    98,372    14,262 
Other comprehensive income:                    
Foreign currency translation adjustment, net of tax   (14,056)   (44,224)   (34,915)   (5,062)
Unrealized gain/ (loss) on available for sale investments, net of tax   17,612    (17,530)   (5,334)   (773)
Total comprehensive income   107,811    100,362    58,022    8,412 
Total comprehensive loss attributable to non-controlling interests shareholders   (3,940)   -    (101)   (15)
Total comprehensive income attributable to ordinary shareholders   111,751    100,362    58,123    8,427 
Weighted average number of ordinary shares used in computing net profit per share                    
Basic   3,620,380,862    3,612,924,848    3,597,746,765    3,597,746,765 
Diluted   3,711,999,000    3,706,306,921    3,689,297,909    3,689,297,909 
Net profit per share attributable to ordinary shareholders                    
Basic   0.03    0.04    0.03    0.00 
Diluted   0.03    0.04    0.03    0.00 

  

 

 

 

(i)Share-based compensation expenses are included in the operating costs and expenses as follows.

 

   For the Three Months Ended 
   March 31, 2025   December 31, 2025   March 31, 2026 
   RMB   RMB   RMB   USD 
Sales and marketing expenses   (1,899)   (1,134)   (1,108)   (160)
General and administrative expenses   (15,527)   (6,531)   (6,134)   (889)
Research and development expenses   (2,501)   (516)   (712)   (103)
Total   (19,927)   (8,181)   (7,954)   (1,152)

 

 

 

 

WATERDROP INC.

RECONCILIATIONS OF GAAP AND NON-GAAP RESULTS

(All amounts in thousands, unless otherwise noted)

 

   For the Three Months Ended 
   March 31, 2025   December 31, 2025   March 31, 2026 
   RMB   RMB   RMB   USD 
Net profit attributable to the Company's ordinary shareholders   108,195    162,116    98,372    14,262 
Add:                    
Share-based compensation expense attributable to the Company's ordinary shareholders   19,750    8,181    7,954    1,152 
Foreign currency exchange loss/(gain)   2,103    (111)   (22)   (3)
Adjusted net profit attributable to the Company's ordinary shareholders   130,048    170,186    106,304    15,411 

 

 

 

FAQ

How did Waterdrop (WDH) perform financially in Q1 2026?

Waterdrop reported strong revenue growth but softer earnings in Q1 2026. Net operating revenue reached RMB1,242.2 million, up 64.8% year-over-year, while net profit attributable to ordinary shareholders was RMB98.4 million, below both the prior-year and prior-quarter figures.

What drove Waterdrop (WDH) revenue growth in the first quarter of 2026?

Growth was driven mainly by the insurance business and AI-enabled initiatives. Insurance-related income rose 74.1% year-over-year, premiums for pre-existing condition insurance increased 24.3%, and first-year premiums via the “AI Insurance Expert” grew 17.7% quarter-over-quarter.

What was Waterdrop (WDH) cash position as of March 31, 2026?

Waterdrop held a substantial cash position at the quarter end. Cash position was RMB2,880.7 million (US$417.6 million) as of March 31, 2026, compared with RMB3,249.0 million as of December 31, 2025, supporting ongoing operations and shareholder return programs.

How profitable was Waterdrop (WDH) in Q1 2026 on a GAAP and non-GAAP basis?

Waterdrop remained profitable but below prior periods. Net profit attributable to ordinary shareholders was RMB98.4 million, while adjusted non-GAAP net profit reached RMB106.3 million, which excludes share-based compensation and foreign currency exchange gains or losses.

What shareholder return actions did Waterdrop (WDH) take through May 31, 2026?

Waterdrop executed both buybacks and a dividend. The company had repurchased about 61.8 million ADSs from the open market for approximately US$120.1 million and paid a cash dividend of around US$10.8 million as part of its ongoing shareholder return program.

How did Waterdrop (WDH) digital clinical trial business perform in Q1 2026?

The digital clinical trial segment delivered modest growth. Revenue from digital clinical trial solutions was approximately RMB24.2 million, up 5.4% year-over-year, with partnerships involving 243 pharmaceutical companies and contract research organizations and 957 patients enrolled.

Filing Exhibits & Attachments

1 document